Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up

10th July 2017 Uncategorised 0

Biogen and AbbVie’s multiple sclerosis drug Zinbryta faces new prescribing restrictions in Europe after regulators there reviewed liver injuries and one death in patients taking the medication. It’s a setback at a crucial time, when tough payers and new challengers—including Roche’s Ocrevus—are roiling the MS field.

More: Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up
Source: fierce